<DOC>
	<DOCNO>NCT00781768</DOCNO>
	<brief_summary>The purpose study compare two different treatment protocol treat nausea vomit patient undergone bone marrow transplant . Patients assign one two treatment group . The first group recieve ondansetron ( Zofran ) tablet combine medicine call dexamethasone give IV . Both drug commercially available . Patients The second treatment consist first two drug , plus newly approve drug know aprepitant ( MK-869 , Emend ) . This combination treatment test . The combination approve FDA chemotherapy regimens know cause lot nausea vomit . It significantly decrease delay ( 24 hour therapy ) nausea vomit see regimen .</brief_summary>
	<brief_title>Odansetron Dexamethasone Alone vs. Odansetron , Dexamethason Apreptant Prevent Nausea</brief_title>
	<detailed_description>This single center , comparative , randomize , double-blind , phase III trial design evaluate efficacy NK-1 antagonist , aprepitant ( MK-869 ) , combination ondansetron dexamethasone prevention acute delayed nausea vomit compare ondansetron dexamethasone patient receive highly emetogenic preparative regimen prior autologous allogeneic ( relate unrelated ) stem cell transplantation . Patients randomize one two treatment : dexamethasone 10 mg IV daily ondansetron 8 mg orally every 8 hour day preparative regimen plus one additional day vs. 7.5 mg IV daily ondansetron 8 mg orally every 8 hour day preparative regimen plus one additional day combine aprepitant , 125 mg orally first day preparative regimen follow 80 mg daily remain day preparative regimen plus three additional day .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis cancer , admit myelosupppresive stem cell transplantation . Included preparative regimen include : TBI/VP16/CY , TBI/CY , BU/CY ( PO &amp; IV ) , BCV Age 18 old Alcohol intake &lt; 100 gm/d last year ( &lt; approximately 5 drink per day ) Renal function : estimate measure CrCl 50 ml/min Liver function : T.Bili &lt; 1.5 , AST &lt; 2x ULN , unless due disease Able swallow tablet capsule Age &lt; 18 High alcohol intake [ &gt; 100 gm/d last year ] Allergy intolerance : ondansetron dexamethasone Renal dysfunction [ measure estimate CrCl &lt; 50 ml/min ] Liver dysfunction [ T.Bili &gt; 1.5 , AST &gt; 2x ULN , unless due disease ] Inability swallow tablet capsule Concurrent condition require systemic steroid use Nonmyeloablative SCT , patient receive condition regimen include [ see inclusion criterion ] History anticipatory nausea vomit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>NK-1 antagonist</keyword>
	<keyword>Nausea vommitting stem cell/marrow transplant population .</keyword>
</DOC>